Table 3.

Clinical trials targeting CD47- SIRP-α axis*.

Drug	Cancer types	Clinical phase	Status/outcomes	Clinical identifier	Clinical Remark
Hu5F9-G4	NHL, DLBCL, NHL, DLBCL	1	Completed	NCT03527147	To evaluate various targeted agents for relapsed/refractory aggressive NHL No results posted
	AML, MDS	1	Completed	NCT02678338	First-in-man safety and dose-finding in relapsed/refractory AML or high risk MDS Adverse events like decline in Hb and red blood cells agglutination Recipients being safely transfused
	Solid Tumor	1	Completed	NCT02216409	Well tolerated Adverse events included transient anemia, hemagglutination, hemagglutination etc.
TTI-621	HM, Solid Tumor	1	Recruiting	NCT02663518	Well-tolerated Activity as monotherapy 29% ORR for diffuse large B-cell lymphoma (DLBCL)
	Solid Tumors, Melanoma, MCC, SQC, BRCA, HPV-Related Malignant Neoplasm, Sarcoma	1	Terminated	NCT02890368	Adverse events as chills, injection site pain and fatigue Well tolerated Systemic and locoregional abscopal effects and potential as an immunotherapy
	LMS	1,2	Recruiting	NCT04996004	No results posted
TTI-622	MM	1	Recruiting	NCT05139225	Few or mild side effects No results posted
ALX148	HNC, HNSCC	2	Recruiting	NCT04675294	To estimate anti-tumor efficacy of pembrolizumab with or without ALX148 No results posted
	GAC	2,3	Not yet recruiting	NCT05002127	Design for patients progressed on or after prior HER2-directed therapy or chemotherapy No results posted
	AML	1,2	Active, not recruiting	NCT04755244	No results posted
	Higher Risk MDS	1,2	Recruiting	NCT04417517	To evaluate safety and tolerability of ALX148 combined with azacitidine No results posted
	Metastatic or Advanced Cancer, Solid Tumor, NHL	1	Active, not recruiting	NCT03013218	A first-in-human phase I trial of ALX148 Favorable hematological safety profile Adverse events as thrombocytopenia and neutropenia with ALX148 plus trastuzumab
	MSS-mCRC	2	Recruiting	NCT05167409	No results posted
	OCA	2	Not yet recruiting	NCT05467670	No results posted
AK117	Neoplasms Malignant	1	Completed	NCT04349969	To evaluate antitumor activity with relapsed or refractory advanced or metastatic solid tumors No results posted
	Neoplasms Malignant	1	Active, not recruiting	NCT04728334	To evaluate the adverse events and dose limiting toxicity in monotherapy No results posted
	AML	1,2	Recruiting	NCT04980885	To evaluate composite complete remission rate No result posted
	MDS	1,2	Recruiting	NCT04900350	No results posted
IBC0966	Advanced Malignant Tumors	1,2	Recruiting	NCT04980690	To evaluate the safety, tolerability and efficacy of IBC0966 for monotherapy
STI-6643	Solid Tumor, Relapsed or Refractory Tumor	1	Recruiting	NCT04900519	To evaluate the safety of STI-6643 for monotherapy No results posted
HX009	Advanced Solid Tumor	2	Recruiting	NCT04886271	To evaluate the ORR in 1 years by monotherapy No results posted
	Relapsed/Refractory Lymphoma	1,2	Recruiting	NCT05189093	No results posted
PF-07257876	NSCLC, SQC, CHN, OCA	1	Recruiting	NCT04881045	To evaluate the safety, pharmacokinetic, pharmacodynamic and potential clinical benefit of PF-07257876 No results posted
PF-07901801	DLBCL	2	Not yet recruiting	NCT05626322	No results posted
	OCA	2	Recruiting	NCT05261490	To improve upon the activity of pegylated liposomal doxorubicin in a safe manner No results posted
Magrolimab	FL, MZL, MCL, CLL, BCL	1	Not yet recruiting	NCT04599634	The safety and efficacy of magrolimab added to venetoclax and Obinutuzumab in relapsed and refractory indolent B-cell malignancies
	Brain Cancer	1	Recruiting	NCT05169944	No results posted
	HM	1	Recruiting	NCT03248479	To confirm the safety and tolerability of magrolimab monotherapy in a relapsed/refractory AML and MDS
	MDS, AML	1,2	Not yet recruiting	NCT05367401	No results posted
AO-176	MM	1,2	Recruiting	NCT04445701	To evaluate the safety and efficacy in Relapsed or Refractory MM No results posted
	Solid Tumor	1,2	Active, not recruiting	NCT03834948	First-in-human, dose escalation and expansion study of AO-176 No results posted
IMC-002	Solid Tumor, Lymphoma	1	Recruiting	NCT04306224	First clinical study to investigate the safety, tolerability, clinical activity of IMC-002 No results posted
	Advanced Cancer	1	Recruiting	NCT05276310	Clinical trial of IMC-002 in patients with advanced cancer failed to standard therapy No results posted
SGN-CD47M	Soft Tissue Sarcoma, CRC, HNSCC, NSCLC, BRCA, OCA, PAAD, GAC, Melanoma	1	Terminated	NCT03957096	Terminated due to sponsor decision
IBI188	Advanced Malignancies	1	Completed	NCT03763149 NCT03717103	Results submitted but not posted
CC-90002	AML, MDS	1	Terminated	NCT02641002	No sufficiently encouraging profile for further dose escalation/expansion
	HM	1	Completed	NCT02367196	No results posted
NI-1801	EOC, TNBC, NSCLC	1	Recruiting	NCT05403554	First-in-human clinical study of NI-1801 with advanced, metastatic, or recurrent solid malignancies No results posted
Gentulizumab	Solid Tumor, NHL	1	Recruiting	NCT05221385	First-in-human, escalating dose trial of gentulizumab No results posted
AUR103	Solid Tumor, AML, MDS, NHL	1	Recruiting	NCT05607199	First in human study evaluating the safety, pharmacokinetics, pharmacodynamics and efficacy of AUR103
SRF231	Solid Cancers, Hematologic Cancers	1	Completed	NCT03512340	First-in-human, dose-escalation and expansion study Results submitted but not posted

* The data source from https://www.clinicaltrials.gov and the latest update date is March 9, 2023. The meaning of abbreviations in this table are the same as in Table 1.